Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Martin Vasatko"'
Autor:
Stepan Coufal, Miloslav Kverka, Jakub Kreisinger, Tomas Thon, Filip Rob, Martin Kolar, Zuzana Reiss, Dagmar Schierova, Klara Kostovcikova, Radka Roubalova, Lukas Bajer, Zuzana Jackova, Martin Mihula, Pavel Drastich, Jana Tresnak Hercogova, Michaela Novakova, Martin Vasatko, Milan Lukas, Helena Tlaskalova-Hogenova, Zuzana Jiraskova Zakostelska
Publikováno v:
Journal of Immunology Research, Vol 2023 (2023)
Background. Tumor necrosis factor-alpha (TNF-α) agonists revolutionized therapeutic algorithms in inflammatory bowel disease (IBD) management. However, approximately every third IBD patient does not respond to this therapy in the long term, which de
Externí odkaz:
https://doaj.org/article/65bf846ae46d4d019cc3d1fd3e4f4af7
Autor:
Zuzana Reiss, Filip Rob, Martin Kolar, Dagmar Schierova, Jakub Kreisinger, Zuzana Jackova, Radka Roubalova, Stepan Coufal, Martin Mihula, Tomas Thon, Lukas Bajer, Michaela Novakova, Martin Vasatko, Klara Kostovcikova, Natalie Galanova, Milan Lukas, Miloslav Kverka, Jana Tresnak Hercogova, Helena Tlaskalova-Hogenova, Zuzana Jiraskova Zakostelska
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 12 (2023)
Crohn’s disease (CD) and ulcerative colitis (UC) are two forms of inflammatory bowel disease (IBD), where the role of gut but not skin dysbiosis is well recognized. Inhibitors of TNF have been successful in IBD treatment, but up to a quarter of pat
Externí odkaz:
https://doaj.org/article/5f297a06b11e4563ad6ccd1dbdc90bc1
Autor:
Filip Rob, Dagmar Schierova, Zuzana Stehlikova, Jakub Kreisinger, Radka Roubalova, Stepan Coufal, Martin Mihula, Zuzana Jackova, Miloslav Kverka, Tomas Thon, Klara Kostovcikova, Lukas Bajer, Pavel Drastich, Jana Tresnak Hercogova, Michaela Novakova, Martin Kolar, Martin Vasatko, Milan Lukas, Helena Tlaskalova-Hogenova, Zuzana Jiraskova Zakostelska
Publikováno v:
PLoS ONE, Vol 17, Iss 12, p e0277576 (2022)
BackgroundUstekinumab, is a new therapy for patients with IBD, especially for patients suffering from Crohn's disease (CD) who did not respond to anti-TNF treatment. To shed light on the longitudinal effect of ustekinumab on the immune system, we inv
Externí odkaz:
https://doaj.org/article/1ce2e1563132443fabce1df4c3d02de5
Autor:
Dagmar Schierova, Radka Roubalova, Martin Kolar, Zuzana Stehlikova, Filip Rob, Zuzana Jackova, Stepan Coufal, Tomas Thon, Martin Mihula, Martin Modrak, Miloslav Kverka, Lukas Bajer, Klara Kostovcikova, Pavel Drastich, Jana Hercogova, Michaela Novakova, Martin Vasatko, Milan Lukas, Helena Tlaskalova-Hogenova, Zuzana Jiraskova Zakostelska
Publikováno v:
Cells, Vol 10, Iss 11, p 3188 (2021)
Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated the longitudinal effect of anti-TNF therapy on gut microbiota composi
Externí odkaz:
https://doaj.org/article/8eaa98d5e195490994072169e9a9f0b2
Autor:
Zuzana Stehlikova, Filip Rob, Martin Kolar, Dagmar Schierova, Jakub Kreisinger, Zuzana Jackova, Radka Roubalova, Stepan Coufal, Martin Mihula, Tomas Thon, Lukas Bajer, Michaela Novakova, Martin Vasatko, Klara Kostovcikova, Natalie Galanova, Milan Lukas, Miloslav Kverka, Jana Hercogova, Helena Tlaskalova-Hogenova, Zuzana Jiraskova Zakostelska
Background Crohn’s disease (CD) and ulcerative colitis (UC) are two forms of inflammatory bowel disease (IBD), where gut but not skin dysbiosis is well recognized. Tumor-necrosis factor alpha (TNFα) blockers have been successful in IBD treatment,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0bcee7559e1b6d7b7005911a2d112930
https://doi.org/10.21203/rs.3.rs-1415112/v1
https://doi.org/10.21203/rs.3.rs-1415112/v1
Publikováno v:
Gastroenterology. 162:S40-S41
INTRODUCTION Both primary strictures and secondary anastomotic strictures are common complications in patients with inflammatory bowel diseases (IBD), especially Crohn’s disease (CD). Balloon dilation has been the gold standard in the endoscopic tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a715ca7434599290cc7805c89de97223
https://doi.org/10.1053/j.gastro.2021.12.083
https://doi.org/10.1053/j.gastro.2021.12.083
Autor:
Milan Lukas, Martin Kolar, Martin Vasatko, Martin Lukas, Dana Duricova, Nadezda Machkova, Veronika Hruba, Karin Cerna, Kristyna Kastylova, Kristyna Kubickova
Publikováno v:
Gastroenterology. 162:S105
INTRODUCTION Despite significant impact biological treatment had on prospects of patients with IBD, there is still a substantial proportion of patients with either secondary loss of response or primary non-response to therapy. Strategies to avert tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f6d009749dd2f824d8eee1b75318be5
https://doi.org/10.1053/j.gastro.2021.12.217
https://doi.org/10.1053/j.gastro.2021.12.217